Cephalotaxane derivatives and their processes of preparation and purification
The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with an acylating compound constituted of a side chain precursor which backbone and functionalization are entirely preformed. The invention also concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula: wherein n=2 (i.e. harringtonine) or n=3 (i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%.
1. A process of purification of natural, synthetic or semi-synthetic crude harringtonines for the preparation of pure harringtonines of the following formula:
wherein n=2 or n=3 in which the total content of impurities is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%, comprising performing one or more chromatographic purification(s), and performing one or more crystallization(s) in which the solvent is water or lower C 1-4 alkanol or an aqueous solvent mixture comprising one or more organic solvents.
2. The process of claim 1 in which the solvent is water.
3. The process of claim 1 in which the solvent is water or an aqueous solvent mixture containing one or more organic solvents.
4. The process of claim 1 in which the organic solvent mixture includes one or more lower C 1-4 alkanol.
5. The process of claim 4 in which the lower alkanol is methanol.
6. The process of purification of claim 1 in which the chromatographic purification is in reverse phase, the solvent is an aqueous solvent containing a lower C 1-4 alkanol, a solvent mixture of equivalent selectivity and a buffer.
7. The process of claim 1 , in which the harringtonine is homoharringtonine.
8. The process of claim 1 , in which the harringtonine is harringtonine.
9. The process of claim 6 , wherein said buffer is based on phosphoric acid and is a salt.
10. A method for treatment of leukemia comprising administering to a patient in need of such therapy an effective amount of a purified and/or solid harringtonine as defined by the following formula:
wherein n=2 or n=3 in which the total content of impurities is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5% for treatment of said leukemia, wherein said harringtonine is administered by an implant.
11. The process of claim 1 , wherein the pure harringtonine is such that n=3 and the total content of impurities is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a homoharringtonine content higher than 97.5%.
12. The process of claim 1 , wherein the pure harringtonine is such that n=2 and the total content of impurities is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonine content higher than 97.5%.
13. The process of claim 1 , wherein the pure harringtonine is a crystalline natural, synthetic or semi-synthetic homoharringtonine having substantially the same DSC curve as set out in FIG. 1 .
14. The process of claim 1 , wherein the pure harringtonine is a crystalline natural, synthetic or semi-synthetic homoharringtonine having substantially the same X-ray diffractogram as set out in FIG. 2 , and substantially the same IR spectrum, in KBr as set out in FIG. 3 .
15. The process of claim 1 , wherein the pure harringtonine is a crystalline natural, synthetic or semi-synthetic homoharringtonine having substantially the same DSC curve as set out in FIG. 1 , substantially the same X-ray diffractogram as set out in FIG. 2 , and substantially the same IR spectrum, in KBr as set out in FIG. 3 .
16. The process of claim 1 , wherein the pure harringtonine is a crystalline natural, synthetic or semi-synthetic harringtonine having substantially the same DSC curve as set out in FIG. 4 .
17. The process of claim 1 , wherein the pure harringtonine is a crystalline natural, synthetic or semi-synthetic harringtonine having substantially the same IR spectrum, in KBr as set out in FIG. 5 .
18. The process of claim 1 , wherein the pure harringtonine is a crystalline natural, synthetic or semi-synthetic harringtonine having substantially the same DSC curve as set out in FIG. 4 , and substantially the same IR spectrum, in KBr as set out in FIG. 5 .